Jagsonpal Pharmaceuticals LimitedJAGSNPHARMCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 2 quarters of data

₹218.37

MCap ₹1,440 Cr

Jagsonpal Pharmaceuticals Limited — Stock analysis & AI research Jagsonpal Pharmaceuticals Limited — Multibagger AI analysis Jagsonpal Pharmaceuticals Limited — Seasonality — best & worst months Jagsonpal Pharmaceuticals Limited — Technical indicators & charts Jagsonpal Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Jagsonpal Pharmaceuticals Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Interest Coverage Stocks 📋 Low Debt Stocks 📋 Promoters Increasing Stake 📋 High Promoter Holding Stocks 📋 Quality Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹82 Cr

Sales · Jun 2026

₹17 Cr

Operating Profit · Jun 2026

21.0%

OPM % · Jun 2026

₹13 Cr

Net Profit · Jun 2026

₹2.00

EPS · Jun 2026

📝 Jagsonpal Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Jagsonpal Pharmaceuticals Limited reported revenue of ₹82 crore for the quarter ended June 2026 (Q1 FY27).

Net profit stood at ₹13 crore. Earnings per share (EPS) came in at ₹2.00.

Operating profit stood at ₹17 crore — an operating margin (OPM) of 21.0%.

Valuation snapshot

At the current price of ₹218.37, JAGSNPHARM has a market capitalisation of ₹1,440 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 24th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 69.36%, foreign institutional investors (FIIs) 2.46%, domestic institutional investors (DIIs) 0.31%, public shareholders 27.88% of Jagsonpal Pharmaceuticals Limited.

Promoter holding rose from 67.89% to 69.36% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹1,440 Cr

Current Price ?

₹218.4

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

5.22

P/S ?

N/A

P/FCF ?

30.64

Enterprise Value ?

₹1,448 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

23.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹82 Cr

PAT — latest qtr ?

₹13 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹8 Cr

Debt to Equity ?

0.03

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

69.36%

Change in promoter holding ?

1.82%

Pledged percentage ?

N/A

Market

Return 3 months ?

-2.5%

Return 6 months ?

13.8%

🗓️ Quarterly results (2 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2025	Jun 2026	YoY %	QoQ %
Sales	73	82	—	—
Operating Profit	16	17	—	—
Other Income	3	3	—	—
Interest	0	0	—	—
Depreciation	2	2	—	—
Profit Before Tax	15	18	—	—
Net Profit	11	13	—	—
EPS	1.67	2.00	—	—
OPM %	22.3%	21.0%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	13	13	13	13	+0.0%
Reserves	146	174	227	263	+15.9%
Borrowings	6	9	9	8	-11.1%
Other Liabilities	30	21	29	32	+10.3%
Total Liabilities	195	217	278	317	+14.0%
Fixed Assets	24	9	94	85	-9.6%
CWIP	0	0	0	0	—
Investments	1	0	0	0	—
Other Assets	170	208	184	231	+25.5%
Total Assets	195	217	278	317	+14.0%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	47	35	55	47	-14.5%
Cash from Investing Activity	-58	-25	-45	-36	+20.0%
Cash from Financing Activity	-0	-9	-12	-12	+0.0%
Net Cash Flow	-11	2	-2	-1	+50.0%
Free Cash Flow	48	35	91	47	-48.4%
CFO/OP	158%	189%	124%	101%	-18.5%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	32	19	18	22	+22.2%
Inventory Days	82	68	58	51	-12.1%
Days Payable	66	35	37	40	+8.1%
Cash Conversion Cycle	48	53	39	33	-15.4%
Working Capital Days	34	52	9	11	+22.2%
ROCE %	25%	17%	23%	23%	+0.0%

👥 Shareholding (latest 4 periods)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	67.54%	67.39%	67.89%	69.36%	+2.2%
FIIs	2.12%	2.12%	2.44%	2.46%	+0.8%
DIIs	0.08%	0.15%	0.22%	0.31%	+40.9%
Public	30.25%	30.34%	29.44%	27.88%	-5.3%
No. of Shareholders	24,653	24,895	26,264	24,826	-5.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	KOPRAN Kopran	₹281.55	1,361	54.5	700	25	8.7%	3.6%	-96.0%	-97.6%	13.9%	-10.0%

❓ Frequently asked questions

What was Jagsonpal Pharmaceuticals Limited's revenue in Q1 FY27?